JP2016519081A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016519081A5 JP2016519081A5 JP2016503128A JP2016503128A JP2016519081A5 JP 2016519081 A5 JP2016519081 A5 JP 2016519081A5 JP 2016503128 A JP2016503128 A JP 2016503128A JP 2016503128 A JP2016503128 A JP 2016503128A JP 2016519081 A5 JP2016519081 A5 JP 2016519081A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- amino acids
- sequence
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001413 amino acids Chemical class 0.000 claims 29
- 125000003275 alpha amino acid group Chemical group 0.000 claims 16
- 102100035361 Cerebellar degeneration-related protein 2 Human genes 0.000 claims 14
- 101000737796 Homo sapiens Cerebellar degeneration-related protein 2 Proteins 0.000 claims 14
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 claims 12
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims 12
- 101000737793 Homo sapiens Cerebellar degeneration-related antigen 1 Proteins 0.000 claims 12
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- 230000014508 negative regulation of coagulation Effects 0.000 claims 7
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 3
- 102100022641 Coagulation factor IX Human genes 0.000 claims 3
- 206010053567 Coagulopathies Diseases 0.000 claims 3
- 208000015294 blood coagulation disease Diseases 0.000 claims 3
- 230000009852 coagulant defect Effects 0.000 claims 3
- 230000015271 coagulation Effects 0.000 claims 3
- 238000005345 coagulation Methods 0.000 claims 3
- 108010039209 Blood Coagulation Factors Proteins 0.000 claims 2
- 102000015081 Blood Coagulation Factors Human genes 0.000 claims 2
- 102100026735 Coagulation factor VIII Human genes 0.000 claims 2
- 201000003542 Factor VIII deficiency Diseases 0.000 claims 2
- 208000009292 Hemophilia A Diseases 0.000 claims 2
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 claims 2
- 239000003114 blood coagulation factor Substances 0.000 claims 2
- 208000011664 congenital factor XI deficiency Diseases 0.000 claims 2
- 201000007219 factor XI deficiency Diseases 0.000 claims 2
- 208000009429 hemophilia B Diseases 0.000 claims 2
- 108010076282 Factor IX Proteins 0.000 claims 1
- 108010054218 Factor VIII Proteins 0.000 claims 1
- 102000001690 Factor VIII Human genes 0.000 claims 1
- 108010054265 Factor VIIa Proteins 0.000 claims 1
- 208000032843 Hemorrhage Diseases 0.000 claims 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 239000004019 antithrombin Substances 0.000 claims 1
- 230000000740 bleeding effect Effects 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 230000023555 blood coagulation Effects 0.000 claims 1
- 230000007812 deficiency Effects 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229960004222 factor ix Drugs 0.000 claims 1
- 229940012414 factor viia Drugs 0.000 claims 1
- 229960000301 factor viii Drugs 0.000 claims 1
- 229960002897 heparin Drugs 0.000 claims 1
- 229920000669 heparin Polymers 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 230000003248 secreting effect Effects 0.000 claims 1
- 238000004904 shortening Methods 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361784590P | 2013-03-14 | 2013-03-14 | |
| US61/784,590 | 2013-03-14 | ||
| PCT/US2014/029541 WO2014153195A1 (en) | 2013-03-14 | 2014-03-14 | Monoclonal antibodies against antithrombin beta complexed with heparin |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016519081A JP2016519081A (ja) | 2016-06-30 |
| JP2016519081A5 true JP2016519081A5 (enExample) | 2017-04-13 |
Family
ID=50680168
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016503128A Pending JP2016519081A (ja) | 2013-03-14 | 2014-03-14 | ヘパリンと結合体化した抗トロンビンβに対するモノクローナル抗体 |
Country Status (18)
| Country | Link |
|---|---|
| US (4) | US20140271660A1 (enExample) |
| EP (1) | EP2970500A1 (enExample) |
| JP (1) | JP2016519081A (enExample) |
| KR (1) | KR20150127202A (enExample) |
| CN (1) | CN105229033B (enExample) |
| AR (1) | AR095499A1 (enExample) |
| AU (1) | AU2014236198A1 (enExample) |
| BR (1) | BR112015021399A2 (enExample) |
| CA (1) | CA2916421A1 (enExample) |
| HK (1) | HK1215261A1 (enExample) |
| MX (1) | MX2015012441A (enExample) |
| PE (1) | PE20160533A1 (enExample) |
| RU (1) | RU2015143696A (enExample) |
| SG (1) | SG11201506886TA (enExample) |
| TW (1) | TW201529602A (enExample) |
| UY (1) | UY35457A (enExample) |
| WO (1) | WO2014153195A1 (enExample) |
| ZA (1) | ZA201507628B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140271660A1 (en) | 2013-03-14 | 2014-09-18 | Bayer Healthcare Llc | Monoclonal antibodies against antithrombin beta |
| EP3146759B1 (en) * | 2014-05-19 | 2021-04-07 | Nokia Solutions and Networks Oy | Re-establishment procedure in dual connectivity networks |
| EP4074730A1 (en) | 2015-06-24 | 2022-10-19 | F. Hoffmann-La Roche AG | Anti-transferrin receptor antibodies with tailored affinity |
| AR106189A1 (es) | 2015-10-02 | 2017-12-20 | Hoffmann La Roche | ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO |
| AR106230A1 (es) | 2015-10-02 | 2017-12-27 | Hoffmann La Roche | Anticuerpos biespecíficos contra el cd20 humano y el receptor de transferrina humano y métodos de uso |
| WO2017158176A1 (en) * | 2016-03-18 | 2017-09-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anti-antithrombin single-domain antibodies and polypeptides comprising thereof |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5578253A (en) | 1978-12-11 | 1980-06-12 | Teikoku Hormone Mfg Co Ltd | Immune measurement of hito antithrombin 3 |
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| BE896543A (fr) | 1983-04-22 | 1983-08-16 | Wallone Region | Ensembles d'anticorps monoclonaux deriges contre les proteines humaines impliquees dans la coagulation et la fibrinolyse du sang |
| JPH0644876B2 (ja) | 1985-12-13 | 1994-06-15 | 株式会社ヤトロン | 抗トロンビン・アンチトロンビン3複合体モノクローナル抗体、及びその製造方法、並びにそれを用いるトロンビン・アンチトロンビン3複合体の免疫定量法、及びそれを用いるトロンビン・アンチトロンビン3複合体の精製方法 |
| JPH0266458A (ja) | 1988-09-01 | 1990-03-06 | Takara Shuzo Co Ltd | ビトロネクチン及びビトロネクチン‐トロンビン‐アンチトロンビン3複合体の測定方法 |
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| AU628960B2 (en) | 1989-04-07 | 1992-09-24 | Teijin Limited | Method of immunologically assaying human thrombin- antithrombin III complex, assay reagent and kit therefor |
| US7084260B1 (en) | 1996-10-10 | 2006-08-01 | Genpharm International, Inc. | High affinity human antibodies and human antibodies against human antigens |
| US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
| JPH0694713A (ja) | 1991-07-31 | 1994-04-08 | Masashi Funayama | アンチトロンビンiii活性の測定方法とそれを用いたアンチトロンビンiii活性の測定キット |
| JPH07238099A (ja) * | 1994-02-25 | 1995-09-12 | Dai Ichi Pure Chem Co Ltd | モノクローナル抗体及びこれを用いる免疫学的測定法 |
| FR2718849B1 (fr) | 1994-04-14 | 1996-06-14 | Pasteur Sanofi Diagnostics | Procédé d'immunodosage de l'antithrombine III activée par un glycosaminoglycane, anticorps monoclonaux correspondants et leur procédé d'obtention. |
| US5753445A (en) | 1994-04-26 | 1998-05-19 | The Mount Sinai Medical Center Of The City University Of New York | Test for the detection of anti-heparin antibodies |
| JP3841364B2 (ja) | 1994-10-18 | 2006-11-01 | 株式会社三菱化学ヤトロン | 抗ヒトビトロネクチン・トロンビン・アンチトロンビンiii 複合体モノクローナル抗体、ハイブリドーマ及び免疫学的測定方法 |
| DK0912738T3 (da) | 1996-05-22 | 2008-11-17 | Viventia Biotech Inc | Antigen-bindende-fragmenter der specifikt detekterer cancerceller, nukleotider der koder fragmenterne og anvendelse deraf til profylakse og detektion af cancere |
| EP0912728A1 (en) | 1996-05-31 | 1999-05-06 | MediGene Aktiengesellschaft | Novel synthetic protein structural templates for the generation, screening and evolution of functional molecular surfaces |
| ES2299425T3 (es) | 1999-05-13 | 2008-06-01 | Gtc Biotherapeutics, Inc. | Antitrombina iii producida geneticamente y formas mutantes de la misma. |
| JP2001321167A (ja) | 2000-05-10 | 2001-11-20 | Cosmo Research Inst | モノクローナル抗体 |
| PT2275449T (pt) | 2000-06-16 | 2016-12-27 | Human Genome Sciences Inc | Anticorpos que se ligam imunoespecificamente a blys |
| US7598055B2 (en) | 2000-06-28 | 2009-10-06 | Glycofi, Inc. | N-acetylglucosaminyltransferase III expression in lower eukaryotes |
| US7625756B2 (en) | 2000-06-28 | 2009-12-01 | GycoFi, Inc. | Expression of class 2 mannosidase and class III mannosidase in lower eukaryotic cells |
| JP2002316999A (ja) | 2001-04-17 | 2002-10-31 | Dai Ichi Pure Chem Co Ltd | モノクローナル抗体 |
| US20090226429A1 (en) | 2001-05-25 | 2009-09-10 | Human Genome Sciences, Inc. | Antibodies That Immunospecifically Bind to TRAIL Receptors |
| WO2005016236A2 (en) | 2003-05-06 | 2005-02-24 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to trail receptors |
| WO2003089575A2 (en) | 2002-04-15 | 2003-10-30 | Human Genome Sciences, Inc. | Antibodies that specifically bind to tl5 |
| EP1530629B1 (en) | 2002-05-31 | 2011-08-31 | The University of Utah Research Foundation | Variants of antithrombin iii |
| EP1382615A1 (en) | 2002-07-15 | 2004-01-21 | Xerion Pharmaceuticals AG | MCAM inhibitors |
| AU2003289716A1 (en) | 2002-09-12 | 2004-04-30 | Incyte Corporation | Molecules for diagnostics and therapeutics |
| RU2262109C2 (ru) | 2002-12-30 | 2005-10-10 | Институт биохимической физики им. Н.М. Эмануэля Российской академии наук | Способ определения концентрации антитромбина iii в плазме крови |
| MXPA05009556A (es) | 2003-03-14 | 2005-11-16 | Wyeth Corp | Anticuerpos contra receptor de il-21 humano y sus usos. |
| GB2404981A (en) | 2003-08-15 | 2005-02-16 | Univ Geneve | Diagnostic method for stroke |
| EP1692184B1 (en) | 2003-11-07 | 2012-03-07 | Immunex Corporation | Antibodies that bind interleukin-4 receptor |
| US7271245B2 (en) | 2004-02-13 | 2007-09-18 | The Scripps Research Institute | Methods and compositions for inhibition of metastasis |
| AU2005271523B2 (en) | 2004-08-03 | 2011-09-15 | Dyax Corp. | hk1-binding proteins |
| JP4829609B2 (ja) | 2004-12-22 | 2011-12-07 | 独立行政法人科学技術振興機構 | ヒト抗体酵素およびその生産方法 |
| JP4942664B2 (ja) | 2005-02-01 | 2012-05-30 | モーフォシス アーゲー | 抗体を単離するためのライブラリおよび方法 |
| WO2009013251A1 (en) | 2007-07-20 | 2009-01-29 | Universite Paris-Sud Xi | Use of mutated antithrombins for treating or preventing coagulation disorders |
| ES2628395T3 (es) | 2007-08-15 | 2017-08-02 | Bayer Pharma Aktiengesellschaft | Anticuerpo regulado por proteasa |
| PT2220221E (pt) | 2007-11-29 | 2015-04-16 | Grifols Therapeutics Inc | Plasmina modificada de forma recombinante |
| ES2346618B1 (es) | 2008-08-14 | 2011-08-03 | Universidad De Murcia | Anticuerpo monoclonal anti antitrombina citrulinada humana y sus usos. |
| NO330078B1 (no) | 2008-09-22 | 2011-02-14 | Optipro As | Fremgangsmåte og apparat for å overvåke slitasje i sikteduker |
| WO2010047830A2 (en) | 2008-10-24 | 2010-04-29 | The Scripps Research Institute | Agents for hcv treatment |
| AR079944A1 (es) | 2010-01-20 | 2012-02-29 | Boehringer Ingelheim Int | Anticuerpo neutralizante de la actividad de un anticoagulante |
| EP3401333B1 (en) | 2010-09-09 | 2021-05-19 | Purdue Research Foundation | Anti-human folate receptor beta antibodies and methods of use |
| US20140356377A1 (en) | 2011-08-25 | 2014-12-04 | Umc Utrecht Holding B.V. | Compounds for use in boosting coagulation |
| JP6095678B2 (ja) | 2011-11-11 | 2017-03-15 | エスアイオーツー・メディカル・プロダクツ・インコーポレイテッド | 薬剤パッケージ用の不動態化、pH保護又は滑性皮膜、被覆プロセス及び装置 |
| US20140271660A1 (en) * | 2013-03-14 | 2014-09-18 | Bayer Healthcare Llc | Monoclonal antibodies against antithrombin beta |
| JP6094713B1 (ja) | 2016-06-30 | 2017-03-15 | 富士ゼロックス株式会社 | 定着部材、定着装置、及び画像形成装置 |
-
2014
- 2014-03-14 US US14/214,267 patent/US20140271660A1/en not_active Abandoned
- 2014-03-14 RU RU2015143696A patent/RU2015143696A/ru not_active Application Discontinuation
- 2014-03-14 HK HK16103100.3A patent/HK1215261A1/zh unknown
- 2014-03-14 WO PCT/US2014/029541 patent/WO2014153195A1/en not_active Ceased
- 2014-03-14 AR ARP140101104A patent/AR095499A1/es unknown
- 2014-03-14 BR BR112015021399A patent/BR112015021399A2/pt not_active IP Right Cessation
- 2014-03-14 AU AU2014236198A patent/AU2014236198A1/en not_active Abandoned
- 2014-03-14 PE PE2015001972A patent/PE20160533A1/es not_active Application Discontinuation
- 2014-03-14 UY UY0001035457A patent/UY35457A/es not_active Application Discontinuation
- 2014-03-14 SG SG11201506886TA patent/SG11201506886TA/en unknown
- 2014-03-14 CN CN201480028085.2A patent/CN105229033B/zh not_active Expired - Fee Related
- 2014-03-14 TW TW103109449A patent/TW201529602A/zh unknown
- 2014-03-14 CA CA2916421A patent/CA2916421A1/en not_active Abandoned
- 2014-03-14 KR KR1020157028131A patent/KR20150127202A/ko not_active Withdrawn
- 2014-03-14 EP EP14722465.3A patent/EP2970500A1/en not_active Withdrawn
- 2014-03-14 US US14/214,382 patent/US9593166B2/en not_active Expired - Fee Related
- 2014-03-14 US US14/770,222 patent/US9908942B2/en not_active Expired - Fee Related
- 2014-03-14 MX MX2015012441A patent/MX2015012441A/es unknown
- 2014-03-14 JP JP2016503128A patent/JP2016519081A/ja active Pending
-
2015
- 2015-10-13 ZA ZA2015/07628A patent/ZA201507628B/en unknown
-
2018
- 2018-02-28 US US15/908,705 patent/US10144784B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016519081A5 (enExample) | ||
| ES2605945T3 (es) | Anticuerpos de unión a Tweak | |
| HRP20161740T1 (hr) | Ljudske molekule za vezanje koje su sposobne neutralizirati viruse influence a filogenetske skupine 1 i filogenetske skupine 2, te viruse influence b | |
| JP2017531642A5 (enExample) | ||
| Hey | History and practice: antibodies in infectious diseases | |
| JP2017071606A5 (enExample) | ||
| JP2019505527A5 (enExample) | ||
| JP2019527678A5 (enExample) | ||
| RU2017102514A (ru) | Гуманизированные анти-тау-антитела | |
| JP2015522252A5 (enExample) | ||
| HRP20200887T1 (hr) | Smjese za inhibiciju masp-2 ovisne aktivacije komplementa | |
| US20220144943A1 (en) | Anti-cd47 antibodies and uses thereof | |
| JP2018531914A5 (enExample) | ||
| BR112019008010A2 (pt) | anticorpo monoclonal isolado ou fragmento imunologicamente ativo do mesmo, anticorpo monoclonal biespecífico isolado, composição farmacêutica, método para tratamento de uma doença em um sujeito humano em necessidade do mesmo, proteína de fusão, epítopo imunodominante codificado pelo gene cd47, e, molécula biológica | |
| JP2016507555A5 (enExample) | ||
| EA202091590A1 (ru) | Антитела против pd-l1 и варианты их применения | |
| JP6954842B2 (ja) | 増強された活性を有する抗体及びその改変方法 | |
| HRP20150439T1 (hr) | Protutijela za humani angiopoietin 2 | |
| JP2020514277A5 (enExample) | ||
| CY1111337T1 (el) | Βελτιωμενα επιλεκτικα πρωτοϊνιδιων αντισωματα και η χρηση αυτων | |
| JP2016501230A5 (enExample) | ||
| HRP20200652T1 (hr) | Ljudska antitijela na fel d1 i metode njihove primjene | |
| RU2018129874A (ru) | Антитела против фактора свертывания xi | |
| HRP20150799T1 (hr) | Sastavi i postupci za protutijela protiv komplementnog proteina c5 | |
| JP2014221758A5 (enExample) |